Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

726 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial
Colombel JF, et al. Gastroenterology 2007 - Clinical Trial. Among authors: Rutgeerts P. PMID 17241859
RESULTS: The percentage of randomized responders in remission was significantly greater in the adalimumab 40-mg eow and 40-mg weekly groups versus placebo at week 26 (40%, 47%, and 17%, respectively; P < .001) and week 56 (36%, 41%, and 12%, respectively; P < .001). ...
RESULTS: The percentage of randomized responders in remission was significantly greater in the adalimumab 40-mg eow and 40-mg weekly groups …
Prevention of duodenal ulcer recurrence by pirenzepine 50 mg twice daily
Rutgeerts P, et al. J Clin Gastroenterol 1987 - Clinical Trial. PMID 3302005
These differences are significantly in favor of pirenzepine (p less than 0.05). Both treatments were well tolerated. Dry mouth was more frequently observed with pirenzepine (14 versus 5 patients). ...
These differences are significantly in favor of pirenzepine (p less than 0.05). Both treatments were well tolerated. Dry mouth was mo …
Crohn's disease of the esophagus
Geboes K, et al. J Clin Gastroenterol 1986. Among authors: Rutgeerts P. PMID 3701011
Controlled trial of metronidazole treatment for prevention of Crohn's recurrence after ileal resection
Rutgeerts P, et al. Gastroenterology 1995 - Clinical Trial. PMID 7768364
RESULTS: At 12 weeks, 21 of 28 patients (75%) in the placebo group had recurrent lesions in the neoterminal ileum as compared with 12 of 23 patients (52%) in the metronidazole group (P = 0.09). The incidence of severe endoscopic recurrence was significantly reduced by metronidazole (3 of 23; 13%) as compared with placebo (12 of 28; 43%; P = 0.02). ...
RESULTS: At 12 weeks, 21 of 28 patients (75%) in the placebo group had recurrent lesions in the neoterminal ileum as compared with 12 of 23 …
A comparison of budesonide with prednisolone for active Crohn's disease
Rutgeerts P, et al. N Engl J Med 1994 - Clinical Trial. PMID 8078530
Corticosteroid-associated side effects were significantly less common in the budesonide group (29 vs. 48 patients, P = 0.003). ...The mean morning plasma cortisol concentration was significantly lower in the prednisolone group than in the budesonide group after 4 weeks (P < 0.001) and 8 weeks (P = 0.02) of therapy, but not after 10 weeks. ...
Corticosteroid-associated side effects were significantly less common in the budesonide group (29 vs. 48 patients, P = 0.003). ...The …
726 results
Jump to page
Feedback